RECRUITING Phase 2 ClinicalTrials.gov

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Sponsor: AstraZeneca • ClinicalTrials.gov ID: NCT05061550

Registry updated: 2026-09-23

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Interventions

Durvalumab (Drug)
Participants will receive Durvalumab via intravenous route.
Oleclumab (Drug)
Participants will receive Oleclumab via intravenous route.
Monalizumab (Drug)
Participants will receive Monalizumab via intravenous route.
Dato-DXd (Drug)
Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
AZD0171 (Drug)
Participants will receive AZD0171 via intravenous route.
Carboplatin (Drug)
Carboplatin as chemotherapy
Cisplatin (Drug)
Cisplatin as chemotherapy
Pemetrexed/Cisplatin (Drug)
Pemetrexed/Cisplatin as chemotherapy
Pemetrexed/Carboplatin (Drug)
Pemetrexed/Carboplatin as chemotherapy
Carboplatin/Paclitaxel (Drug)
Carboplatin/Paclitaxel, as chemotherapy
Volrustomig (Drug)
Participants will receive Volrustomig via intravenous route.
Rilvegostomig (Drug)
Participants will receive Rilvegostomig via intravenous route.

Eligibility criteria

Inclusion Criteria: * Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB). * WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ and bone marrow function. * Provision of tumour samples (newly acquired or archival tumour tissue \[≤ 6 months old\]) to confirm Programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) status. * Adequate pulmonary function. Exclusion Criteria: * Participants with sensitising EGFR mutations or ALK translocations. * Participants with baseline PD-L1 expression status \<1% (Arms 6 and 7 only). * Active or prior documented autoimmune or inflammatory disorders. * Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement. * History of another primary malignancy. * Participants with small-cell lung cancer or mixed small-cell lung cancer. * History of active primary immunodeficiency. * History of non-infectious interstitial lung disease (ILD) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. * Participants who have preoperative radiotherapy treatment as part of their care plan. * Participants who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon at baseline, to obtain potentially curative resection of primary tumour. * QTcF (QT interval corrected by Fridericia's formula) interval ≥ 470 ms. * Any medical contraindication to treatment with chemotherapy as listed in the local labelling. * Participants with moderate or severe cardiovascular disease. * Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. * Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions. * Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Participants who received agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, and anti-LIF agents are also excluded. Participants who have received previous treatment with a TROP2 targeting ADC or with another ADC containing a chemotherapy agent that inhibits TOP1 activity are also excluded. * Current or prior use of immunosuppressive medication within 14 days before the first dose of study interventions. * Active or uncontrolled infections including HBA, HBV, HCV, and HIV.

Conditions

Non-small Cell Lung Cancer

Locations

Research Site — Little Rock, Arkansas, United States
Research Site — Los Angeles, California, United States
Research Site — Oakland, California, United States
Research Site — New Haven, Connecticut, United States
Research Site — Stuart, Florida, United States
Research Site — Gainesville, Georgia, United States
Research Site — Chicago, Illinois, United States
Research Site — Baltimore, Maryland, United States
Research Site — Baltimore, Maryland, United States
Research Site — Boston, Massachusetts, United States
Research Site — Saint Louis Park, Minnesota, United States
Research Site — Omaha, Nebraska, United States
Research Site — Buffalo, New York, United States
Research Site — Cleveland, Ohio, United States
Research Site — Pittsburgh, Pennsylvania, United States
Research Site — Chattanooga, Tennessee, United States
Research Site — Memphis, Tennessee, United States
Research Site — Nashville, Tennessee, United States
Research Site — Nashville, Tennessee, United States
Research Site — Nashville, Tennessee, United States
Research Site — Houston, Texas, United States
Research Site — Houston, Texas, United States
Research Site — Fairfax, Virginia, United States
Research Site — Edmonds, Washington, United States
Research Site — Seattle, Washington, United States
Research Site — Ghent, Belgium
Research Site — Ghent, Belgium
Research Site — Roeselare, Belgium
Research Site — Edmonton, Alberta, Canada
Research Site — Winnipeg, Manitoba, Canada
Research Site — Montreal, Quebec, Canada
Research Site — Montreal, Quebec, Canada
Research Site — Avignon, France
Research Site — Bobigny, France
Research Site — Bordeaux, France
Research Site — Limoges, France
Research Site — Rennes, France
Research Site — Rouen, France
Research Site — Suresnes, France
Research Site — Toulon, France
Research Site — Kecskemét, Hungary
Research Site — Székesfehérvár, Hungary
Research Site — Tatabánya, Hungary
Research Site — Törökbálint, Hungary
Research Site — Dublin, Ireland
Research Site — Dublin, Ireland
Research Site — Dublin, Ireland
Research Site — Galway, Ireland
Research Site — Aviano, Italy
Research Site — Brescia, Italy
Research Site — Catanzaro, Italy
Research Site — Florence, Italy
Research Site — Genova, Italy
Research Site — Meldola, Italy
Research Site — Milan, Italy
Research Site — Monza, Italy
Research Site — Padova, Italy
Research Site — Perugia, Italy
Research Site — Pisa, Italy
Research Site — Roma, Italy
Research Site — Rozzano, Italy
Research Site — Lisbon, Portugal
Research Site — Lisbon, Portugal
Research Site — Lisbon, Portugal
Research Site — Lisbon, Portugal
Research Site — Porto, Portugal
Research Site — Porto, Portugal
Research Site — Porto, Portugal
Research Site — Busan, South Korea
Research Site — Chungcheongbuk-do, South Korea
Research Site — Seongnam-si, South Korea
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea
Research Site — Suwon, South Korea
Research Site — Suwon, South Korea
Research Site — A Coruña, Spain
Research Site — Alicante, Spain
Research Site — Barcelona, Spain
Research Site — Barcelona, Spain
Research Site — Córdoba, Spain
Research Site — Madrid, Spain
Research Site — Majadahonda, Spain
Research Site — Málaga, Spain
Research Site — Reus, Spain
Research Site — Seville, Spain
Research Site — Terrassa, Spain
Research Site — Valencia, Spain
Research Site — Liuying, Taiwan
Research Site — New Taipei City, Taiwan
Research Site — Tainan, Taiwan
Research Site — Taipei, Taiwan
Research Site — Taipei, Taiwan
Research Site — Ankara, Turkey (Türkiye)
Research Site — Ankara, Turkey (Türkiye)
Research Site — Ankara, Turkey (Türkiye)
Research Site — Istanbul, Turkey (Türkiye)
Research Site — Izmir, Turkey (Türkiye)

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment